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ABSTRACT
Gene editing mediated by oligonucleotides has been
shown to induce stable single base alterations in
genomic DNA in both prokaryotic and eukaryotic
organisms. However, the low frequencies of gene
repair have limited its applicability for both basic
manipulation of genomic sequences and for the
development of therapeutic approaches for genetic
disorders. Here, we show that single-stranded
oligodeoxynucleotides (ssODNs) containing a
methyl-CpG modification and capable of binding to
the methyl-CpG binding domain protein 4 (MBD4)
are able to induce >10-fold higher levels of gene
correction than ssODNs lacking the specific modifi-
cation. Correction was stably inherited through cell
division and was confirmed at the protein, transcript
and genomic levels. Downregulation of MBD4
expression using RNAi prevented the enhancement
of gene correction efficacy obtained using the
methyl-CpG-modified ssODN, demonstrating the
specificity of the repair mechanism being recruited.
Our data demonstrate that efficient manipulation of
genomic targets can be achieved and controlled
by the type of ssODN used and by modulation of
the repair mechanism involved in the correction
process. This new generation of ssODNs represents
an important technological advance that is likely to
have an impact on multiple applications, especially
for gene therapy where permanent correction of the
genetic defect has clear advantages over viral and
other nonviral approaches currently being tested.
INTRODUCTION
Manipulation of genomic sequences through gene
trapping or gene targeting technologies has a wide
spectrum of applications ranging from site-directed
mutagenesis of bacterial vectors to development of
animal models through DNA recombination technologies.
Among those, gene editing can be used to target speciﬁc
gene defects and restore protein expression for therapeutic
applications (1–5). To date, however, the use of gene
editing has been limited and is still at an early stage of
development.
Single-stranded oligodeoxynucleotides (ssODNs) have
been shown to be able to alter single nucleotides and
induce stable alterations at the genomic level (3,6). Gene
repair mediated by ssODNs takes advantages of speciﬁc
repair mechanisms present in the cells that are able to
recognize the presence of mismatches in genomic DNA.
ssODNs complementary to the target sequence but con-
taining a mismatch at the base targeted for modiﬁcation
are used as templates for the correction process. Once
introduced into the cell, they have been shown to anneal
to the genomic DNA sequence targeted for repair and
initiate the repair process (7) leading to a single nucleotide
exchange that is stably inherited throughout cell division.
The technology has been successfully applied in diﬀerent
cell types including bacterial, yeast and mammalian cells
(1,3,8–12).
Oligonucleotide-mediated gene correction has been
investigated in several eukaryotic cell type as well as dif-
ferent models of genetic disorders. Correction has been
successfully demonstrated in hepatocytes (13–16), retinal
cells (17,18), bone marrow-derived cells (19) and muscle
cells (5,9,10,20–22). The level of correction varies
depending on the cell type being targeted suggesting that
the repair process involved is diﬀerentially regulated in
diﬀerent cell types.
In skeletal muscle, the major focus of ssODN-mediated
gene editing has been the treatment of genetic disease, in
particular Duchenne muscular dystrophy (DMD). This
disease is characterized by mutations in the dystrophin
gene that lead to complete absence of dystrophin protein
expression, progressive muscle degeneration andweakness,
and in most of the cases death by the age of 30 years.
Targeted single base alterations of the dystrophin gene
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using mouse and dog models of DMD (5,9,10,20,21).
Correction can be obtained in mature myoﬁbers (5,10) as
wellasmuscleprogenitorcells(10),suggestingthatoligonu-
cleotides can target both postmitotic cells as well as replica-
ting cells and can achieve frequencies of up to 10%
depending on the strand targeted for repair and the type
of mismatch created by the oligonucleotide (5,10,20,21).
The past few years have seen a considerable expansion
of the application of gene editing to neuromuscular
disorders. Oligonucleotides can be used not only to
correct dystrophin gene defects due to single point
mutations, but also to treat frameshift deletions by dis-
rupting intron/exon consensus sequences to redirect
mRNA assembly and splicing and induce the expression
of novel in-frame transcripts (5,21). Along the same line,
ssODNs have been shown to target and correct a splicing
regulatory element in the SMN2 gene and to restore SMN
protein expression in human ﬁbroblasts (22), highlighting
the potential of this technology for the treatment of
spinal muscular atrophy, another debilitating neuromus-
cular disorder for which there is currently no eﬀective
treatments.
The mechanisms that lead to the repair process remain
unclear, but appear to involve multiple steps. The ﬁrst step
requires the annealing of the ssODN to the targeted
genomic sequence through the interaction of proteins
such as Rad51, Rad54 and XRCC2 (23–25). The second
step, the correction of the single base pair mismatch, is less
well characterized. Initial data suggested that correction is
mediated by mismatch repair (MMR) mechanisms that
recognize the mismatch created by the annealing of the
ssODN to the genomic DNA (26). Proteins involved in
MMR appear to be crucial for the ssODN-mediated
base exchange at least in yeast (7). In some mammalian
cells, however, gene correction can occur even in the
absence of MMR (27,28), suggesting that diﬀerent
mechanisms may operate to facilitate ssODN-mediated
gene repair under diﬀerent cellular contexts.
Homologous recombination, nucleotide exchange repair
and double-strand break repair have all been implicated
as potential mechanistic pathways (29–31), and it is not
clear if the diﬀerent frequencies of gene correction
detected in diﬀerent cell types are in part due to diﬀerent
mechanisms being recruited. This hypothesis led us to
investigate whether ssODN-mediated gene correction
frequencies could be improved by designing ssODNs
capable of activating speciﬁc repair mechanisms in the
cells targeted for repair.
Deamination of 5-methylcytosine is among the most
prominent genomic alterations in mammalian cells with
rates up to 300 events per genome per day (32,33). Loss
of the amino group leads the spontaneous conversion of
5-methylcytosine (m
5C) into thymine which, if left
unrepaired, would lead to the accumulations of C:G-to-
T:A mutations (34,35). The presence of 5-methylcytosines
and the frequency of mutation at such bases in the context
of m
5CpG sites contribute to genetic variation and are
implicated in tumorigenesis (36,37). Repair of the
mismatch created by the deamination of 5-methylcytosine
requires the presence of speciﬁc repair mechanisms
capable of recognizing the mismatch that arises as a
result of the deamination. Recognition of deamination
events in the context of m
5CpG sites is mediated by the
base excision repair (BER) mechanism through the
speciﬁc activation of the methyl-CpG binding domain
protein 4 (MBD4). MBD4 (also known as MED1) plays
a crucial role in maintaining genome integrity by
recognizing G:T or G:U mismatches at m
5CpG sites on
double-stranded DNA (38,39). MBD4 was originally
identiﬁed in a yeast two-hybrid screen due to its interac-
tion with MLH1, an important component of the MMR
mechanism, which led to the hypothesis that the two
systems could be linked (38,40). To date, however, the
role of the interaction between MBD4 and MLH1 has
yet to be clariﬁed (41). In vitro studies have shown that
MBD4 can eﬃciently recognize and hydrolyze G:T or
G:U mismatches at hemi-methylated m
5CpG sites.
Furthermore, a m
5CpG context, although preferred, is
not absolutely necessary as G:T and G:U mismatches in
nonmethylated CpG sequences can also be recognized and
processed, although at a reduced rate (39). Binding of
MBD4 to the mismatched T or U leads to glycosylation
and removal of the base without altering the sugar phos-
phate backbone of the DNA. The apurinic site that is
generated by MBD4 is then processed by speciﬁc
endonucleases and ligases which are required to direct
the addition of a new cytosine on this site and to
complete the repair process (42,43).
We have designed a new generation of ssODNs contain-
ing a methyl-CpG modiﬁcation and tested their ability to
mimic, when annealed to the genomic sequence targeted
for correction, the G:T mismatch that would occur upon
deamination of 50-methylcytosines (to become thymine) in
the genomic DNA targeted for correction. Due to the high
frequencies at which this process occurs in nature, we
hypothesized that the use of these ssODNs could be
much more eﬃcient in directing stable single base
alterations at the genomic level. Their ability to speciﬁ-
cally activate the BER repair by recruiting MBD4 and
to induce single base alterations was tested in muscle
cells using a GFP reporter system. This system allowed
us to determine the eﬃcacies of gene correction of an
m
5CpG-containing ssODN and to compare its eﬃcacy
to targeting ssODNs either lacking any modiﬁed cytosines
or containing a 5-methylcytosine but not in the context of
a CpG dinucleotide, neither of which would be expected to
recruit MBD4. We demonstrate that gene correction
frequencies were consistently higher when an ssODN con-
taining a methyl-CpG and capable of recruiting MBD4
was used. These studies expand the potential applications
of ssODNs in inducing single base alterations at the
genomic level and further advance this technology into
therapeutic applications for the treatment of many
disorders and in particular muscle diseases.
MATERIALS AND METHODS
Oligonucleotide synthesis
ssODNs were purchased from MWG Biotech Inc. (High
Point, NC, USA). All ssODNs were labeled at the 50-end
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of phosphorothioate bases to increase stability of ssODNs
from endonucleases. Oligonucleotides were HPLC
puriﬁed and exhibited a single peak of the expected molec-
ular weight as determined by MALDI-TOF mass spec-
troscopy analysis.
Plasmid constructs
The pGFPmut vector was generated using the
QuickChange II Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA), following the manufac-
turer’s instructions. The pEGFP-N3 vector (BD
Bioscience, Clontech, CA, USA) was annealed with a
forward primer (GFPmut forward: 50-GACCTACGGC
GTGCAGTGATTCAGCCGCTACCCCGAC-30) and a
reverse primer (GFPmut rev: 50-GTCGGGGTAGCGGC
TGAATCACTGCACGCCGTAGGTC-30) designed to
induce the C-to-A transversion in position +213 of the
GFP coding sequence. Initial denaturation was carried out
at 95 C for 3min, followed by a 20-cycle step of
denaturation at 95 C for 3s, annealing at 58 C for 1min
and extension at 68 C for 6min. The PCR product (1ml)
was digested overnight at 37 C with DpnI and trans-
formed in DH5a competent cells (Invitrogen, Carlsbad,
CA, USA). Positive clones were selected by restriction
endonuclease analysis and the C-to-A mutation was con-
ﬁrmed by direct sequencing using an Applied Biosystems
ABI377 automated sequencer.
The pGEX3.MBD4 plasmid was generated by inserting
the MBD4 coding sequence into the BamHI and XhoI
sites of the pGEX3 vector (Amersham GE Healthcare
Bio-Sciences Corp., Piscataway, NJ, USA). The mouse
cDNA encoding MBD4 was obtained by direct cloning
of PCR products encoding the MBD4 cDNA (GenBank
accession number NM_010774). The MBD4 gene
encoding full-length cDNA was obtained by direct ampli-
ﬁcation of a cDNA library using a forward primer
(MBD4-forw-BamHI: 50-GCAGCAGGGATCCGAGA
GCCC-30) and a reverse primer (MBD4-rev-XhoI: 50-CT
CGAGATAGACTTAATTTTTCATG-30). Ampliﬁcation
was carried out for 30 cycles in the presence of Pfu DNA
polymerase (Stratagene) at an annealing temperature of
65 C for 1min and an extension temperature of 68 C
for 2min. Ampliﬁcation was terminated by an additional
extension of 30min at 72 C. Amplicons were digested with
BamHI and XhoI. PCR products were run on a 1.2%
agarose gel and puriﬁed using the gel extraction kit
(Qiagen, Valencia, CA, USA) as previously described
(5). Vector sequences were conﬁrmed using an ABI377
automated sequencer.
Cell culture and transfection
Myoblasts were derived from limb muscle of neonatal C57
mice as previously described (44). For growth, cells were
plated on dishes coated with 5mg/ml laminin (Invitrogen
Corp.) and maintained in growth medium (GM) consist-
ing of Ham’s F10 nutrient mixture (Mediatech, Herndon,
VA, USA) supplemented with 20% fetal bovine serum,
penicillin and streptomycin.
Myoblasts were plated in wells of 6-well dishes
(10
4cells/well) 12h prior to transfection. ssODNs (10 mg)
were complexed with 1ml of Lipofectamine 2000
(Invitrogen Corp.) for 30min at room temperature in a
total volume of 0.5ml of Ham’s F10 nutrient mixture. The
complex was then added to the wells containing 1.5ml of
GM. Transfections were stopped by replacing the
transfection solution with fresh GM.
Expression of recombinant MBD4 protein
Expression constructs of wild-type MBD4 protein were
propagated in Escherichia coli strain XL-1 Blue, as
previously described (38,45). BL21(DE3)(pLysS) cells
transformed with the expression vectors were grown to
OD600 0.4 and induced with 1mM IPTG at 37 C for
2h. Cells were collected by centrifugation and lyzed in
10mM Tris–HCl (pH 8.0), 500mM NaCl, 0.1% Nonidet
P-40 (NP-40), 10% glycerol and ‘Complete’ protease
inhibitors (Boehringer-Mannheim Biochemicals,
Indianapolis, IN, USA). After clariﬁcation by centri-
fugation at 12000g, the soluble protein fraction was
diluted in 150mM NaCl and b-mercaptoethanol (7mM)
was added. Puriﬁcation of recombinant proteins was con-
ducted as previously earlier (46). Brieﬂy, the sample was
applied to a 5-ml Q Sepharose anion exchange column
(Amersham) connected in series to a 5-ml SP Sepharose
cation exchange column (Amersham). After disconnecting
the Q Sepharose column, the SP Sepharose column was
washed and elution was performed with buﬀer containing
1.5M NaCl. The SP Sepharose eluate was applied to a
1.5-ml nickel-chelating Sepharose column (Amersham).
Recombinant MBD4 protein was eluted with 5ml of
10mM Tris–HCl (pH 8.0), 300mM NaCl, 10% glycerol,
2mMb-mercaptoethanol and 150mM imidazole. MBD4
protein was further puriﬁed by size-exclusion chroma-
tography using a Superdex 200 PC 3.2/30 gel-ﬁltration
column with a SMART chromatography system
(Pharmacia Laboratories, Piscataway, NJ, USA), as
previously earlier (45,46). The ﬁnal MBD4 preparation
was estimated to be 95% pure by SDS–PAGE. Upon
the addition of 10% glycerol, puriﬁed MBD4 fractions
were frozen and stored in liquid nitrogen. Protein concen-
tration was determined with the Bio-Rad protein assay
(Bio-Rad, Hercules, CA, USA), using bovine gamma
globulin as a standard.
Flow cytometry
Fluorescence was measured using a Beckton Dickinson
FACScalibur ﬂow cytometry (Becton Dickinson,
Franklin Lakes, NJ, USA). Cells were trypsinized and
harvested at diﬀerent time after transfection, resuspended
in 0.5% BSA, 2mM EDTA in PBS and processed imme-
diately. For each analysis, a total of 2 10
4cells were
used. Experiments were repeated in triplicate for each
time point analyzed and a total of three independent
experiments were performed.
For DNA content analysis, cells were ﬁxed in 70% ice-
cold ethanol, washed in PBS and resuspended in 0.5ml of
PBS containing 50mg/ml RNAse A, 1% FBS and 2.5mg/
7470 Nucleic Acids Research, 2009,Vol.37, No. 22ml propidium iodide. Analyses were performed using
2 10
4 cells.
Western blot analysis
Cells were lyzed in RIPA buﬀer [50mM Tris–HCl (pH
7.4), 150mM NaCl, 0.5% deoxycholate and 1% Nonidet
P-40] containing aprotinin (20mg/ml), leupeptin (20mg/
ml), phenylmethylsulfonyl ﬂuoride (10mg/ml) and
sodium orthovanadate (1mM). Total protein in the
extract was determined by the Bio-Rad protein assay.
Immunoblot analysis was performed as previously
described (10,47). Total protein from each sample
(200mg) was separated by electrophoresis (20mA for
1.5h) using 12% SDS-polyacrylamide gels, and then
transferred (250mA for 1h) onto nitrocellulose
membranes. Membranes were probed overnight at 4 C
with an antibody directed toward the C-terminal region
of the GFP protein (1GFP63; Santa Cruz Biotechnologies,
Santa Cruz, CA, USA) or an antibody directed toward the
N-terminal domain of the MBD4 protein (Abcam Inc.,
Cambridge, MA, USA) (21,47). The membranes were
blocked with 5% milk in PBS for 1h at room temperature.
Blots were washed with 0.05% Tween-20 in PBS and
then incubated with a horseradish peroxidase-coupled
anti-mouse secondary antibody (Amersham). Speciﬁc
antibody binding was detected using an enhanced
chemiluminescent system (Amersham).
Genomic DNA and restriction endonuclease analysis
Cultured myoblasts were rinsed twice with PBS and
genomic DNA was extracted using the Wizard Genomic
DNA extraction kit (Promega, Madison, WI, USA)
according to the manufacturer’s instructions. Total
genomic DNA (1mg) was digested overnight at 37 C with
5Uo fHinfIo rBtsI, puriﬁed using Amicon Microcon-
PCR Centrifugal Filter Devices (Millipore Corporation,
Bedford, MA, USA), and resuspended in 20mlo fH 20.
For each ampliﬁcation reaction, 5ml of digested genomic
DNA was subjected to ampliﬁcation using the forward
primer (GFP-forw: 50-GCTAGCGCTACCGGTCGCCA
C-30) speciﬁc to region  17 to  2 of the GFP open
reading frame (ORF), and the reverse primer (GFP-rev:
50-CCTTGAAGTCGATGCCCTTC-30) complementary
to the region +397 to +377 of the ORF.
Real-time PCR was performed using a My iQ single-
color detection system (Bio-Rad) at the following thermal
cycler conditions: 95 C for 10min followed by 45 cycles of
a 3-step reaction consisting of denaturation at 95 C for
30s, annealing at 60 C for 1min and extension and data
collection at 72 C for 30s. Amplicons were separated on
1.5% agarose gels and PCR products were puriﬁed using
the Qiagen gel extraction kit (Qiagen). DNA sequencing
was carried out using an Applied Biosystems ABI377
automated sequencer.
RT–PCR
Total RNA was extracted from cultured myotubes using
TRI-REAGENT (Sigma, St. Louis, MO, USA). For each
reaction, 2mg of RNA was treated with 1U of DNase I
(GIBCO/BRL) at room temperature and reverse
transcribed using the ﬁrst strand cDNA synthesis kit
(Invitrogen) in the presence of SuperscriptIII
(Invitrogen) to a ﬁnal volume of 20ml. Of those, 10ml
were digested overnight with 5U HinfIo rBtsI in a ﬁnal
volume of 20ml. The remaining 10ml of undigested cDNA
obtained after reverse transcription were brought to a ﬁnal
volume of 20ml containing isomolar concentrations of salt
and glycerol and were used to normalize transcript levels.
PCR reactions were carried out using 4ml of digested
product in the presence of the GFP primers described
earlier. Each ampliﬁcation mixture contained 25pmols
of appropriate primer, 10% DMSO, 0.5U Master Taq
DNA polymerase (Takara, Panvera Corp., Madison,
WI, USA), and 5mM of each deoxyribonucleotide
triphosphate. After an initial step of denaturation at
95 C for 5min, ampliﬁcation was performed for 35
cycles at 95 C for 1min followed by annealing at 55 C
for 3min and extension at 72 C for 2min. Ampliﬁcation
reactions were terminated by an additional extension step
at 72 C for 10min and products were fractionated on
1.5% agarose gels.
Electrophoretic mobility shift assay
An oligonucleotide homologous to the region of the GFP
gene targeted for correction and ssODNs were synthesized
by MWG and puriﬁed by HPLC. Targeting and control
oligonucleotides were identical to the one previously
described (Figure 1), but lacked the CY3 modiﬁcation at
their 50-end. The probe was end-labeled with [g-
32P]ATP
using T4 polynucleotide kinase (Amersham).The ability of
MBD4 to form a complex with the m
5CpG ssODN alone
was investigated using the m
5CpG
GFP labeled at its 50-end
with [g-
32P]ATP. Unincorporated label was removed
with G25 spin columns (Amersham). Control and target-
ing ssODNs were annealed to equal amounts
( 100000c.p.m.) of radiolabeled probe using a thermal
cycler at the following setting conditions: 95 C for
5min for the initial denaturation step, followed by 80 C
for 5min, 75 C for 5min, 70 C for 15min, 55 C for
15min, 37 C for 15min and 20 C for 20min. One
microgram of recombinant MBD4 protein was incubated
in binding buﬀer [50mM Tris–HCl (pH 7.5), 2.5mM
dithiothreitol, 2.5mM EDTA, 250mM NaCl, 5mM
MgCl2 and 20% glycerol] in the presence of 1mg
of Poly(dI-dC):Poly(dI-dC) competitor (Amersham)
for 15min at room temperature. Double-stranded
oligonucleotides were then added to the mixture and
incubated for an additional 15min. Samples were loaded
on 5% polyacrylamide gels and resolved at 200V for 2h.
Gels were dried for 1h at 80 C prior autoradiographic
exposure.
siRNA treatment
The target sites were predicted in silico using on-line
tools from Invitrogen Corp (http://bbiserv.techfak
.uni-biecefeld.de/mfold/). In brief, the sequences targeted
by the Stealth
TM siRNA were listed as residues 589–614 of
the ORF with the following sequence: 50-GCAGCCAAA
UGAAACUGACGUUUCA-30 and 30-CGUCGGUUUA
CUUUGACUGCAAAGU-50. The negative control
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TM siRNA used were: 50-GCAACAAGUAACAG
UCAUGUCGUCA-30 and 30-CGUUGUUCAUUGUCA
GUACAGCAGU-50. No homologous sequences were
found in mouse genome. The double-stranded siRNAs
were synthesized chemically and modiﬁed into stealth
siRNA (Invitrogen Corp) to enhance the stability
in vitro. Transfection of the siRNAs was performed
using Lipofectamine 2000 (Invitrogen) following the man-
ufacturer’s instructions. Eﬃcient silencing was demon-
strated by real-time PCR in cells transfected with the
siRNAs and was performed on RNA isolated at diﬀerent
time after siRNA transfection (Figure 9). First strand
cDNA was prepared and reverse transcribed into cDNA
using SuperScript III Reverse Transcriptase (Invitrogen)
according to the manufacturer’s protocol. Quantitative
real-time RT–PCR was performed using a My iQ single-
color detection system (Bio-Rad) using the following
thermal cycler conditions: 95 C for 10min followed by
45 cycles of a 3-step reaction consisting of denaturation
at 95 C for 30s, annealing at 60 C for 1min and extension
and data collection at 72 C for 30s. The primers
RTMBD4-forw (50-GATGTATACTTTATCAGCCCAC
AAG-30) and RTMBD4-rev (50-CTGGCGACTCTGAA
GTACCAC-30) were used to detect MBD4 mRNA.
Transcripts levels were normalized to those of GAPDH
using the following primers: GAPDH-forw: 50-TGCGAC
TTCAACAGCAACTC-30; GAPDH-rev: 50-ATGTAGG
CCATGAGGTCCAC-30 as described earlier(48).
Statistical analysis
Data are presented as means and standard deviations.
Comparisons between groups were done using Student’s
t-test assuming two-tailed distribution and unequal
variances.
RESULTS
The GFP reporter system and assay
We have established a reporter system and used it to
follow gene repair over time in muscle cells. The
pGFPmut vector contains a single point mutation (a
C-to-A transversion at position +213 of the coding
region), which creates a TGA stop codon and abolishes
GFP protein expression in mammalian cells (Figure 2).
The plasmid was transfected into murine myoblasts and
a stable cell line was selected by G418 using the neomycin
resistance gene encoded by the plasmid. Expression of
GFP mRNA transcripts was conﬁrmed using RT–PCR.
Genomic DNA analysis performed using real-time PCR
revealed the presence of 1.4 copies of integrated vector per
cell. No GFP protein expression was detected either by
western blot, ﬂow cytometry or direct examination by ﬂu-
orescence microscopy in those cultures.
The ssODNs were designed to target and induce single
base pair alterations within the early termination codon
and to restore expression of GFP protein (Figure 1). The
COR
GFP ssODN was designed to correct the C-to-A
transversion of the pGFPmut vector, thus restoring
wild-type GFP protein expression. The m
5CpG
GFP
ssODN contains a 5-methylcytosine adjacent to the base
that creates the mismatch (the targeting base). Annealing
of the m
5CpG
GFP ssODN to the mutant GFP sequence
targets the T of the TGA stop codon, creating a G:T
mismatch in the context of a m
5CpG sequence, precisely
mimicking the situation in which MBD4 recognizes the
deamination of 5-methylcytosine. Correction of the
mismatch will convert the TGA codon into a CGA
codon, restoring the expression of a full-length GFP
protein containing a single amino acid substitution (an
arginine in place of a cysteine) compared with wild-type
GFP protein. The eﬀects of 5-methylcytosine modiﬁcation
of the targeting base itself, but not in the context of an
m
5CpG sequence, were analyzed using a targeting ssODN
(m
5CpC
GFP) in which a 5-methylcytosine creates a
mismatch with the mutant base in the GFP sequence.
Correction of the mismatch induced by the m
5CpC
GFP
should result in an A-to-G substitution, eliminating the
stop codon and creating a missense mutation (a
tryptophan in place of a cysteine) rather than a true res-
toration of the wild-type sequence (as with the COR
GFP
ssODN). A nontargeting (‘perfect match’) ssODN
(CTL
GFP), perfectly complementary to the mutant GFP
sequence and therefore unable to activate any repair
mechanism and induce any single base pair alteration,
was used as a negative control (Figure 1).
Binding of MBD4 to ssODN/target sequence complex
We used electrophoretic mobility shift assays (EMSA) to
test whether recombinant MBD4 would recognize speciﬁc
mismatches and to determine if binding of ssODNs con-
taining a methyl-CpG modiﬁcation would eﬃciently
recruit the MBD4 protein. ssODNs were annealed to an
oligonucleotide
32P-labeled probe homologous to the
region of the pGFPmut vector targeted for correction.
Reactions were carried out in the presence or absence of
recombinant MBD4 (Figure 2). Inclusion of ssODNs in
the reaction mixture resulted in a complex with the labeled
probe (Figure 2, lower arrow). A speciﬁc supershift,
resulting from the binding of MBD4, was detected only
when the probe was annealed to the m
5CpG
GFP ssODN
and incubated with MBD4 but not when the recombinant
protein was incubated with the probe annealed to any of
the other ssODNs (Figure 2, upper arrow). No binding
was detected when MBD4 was incubated with
m
5CpG
GFP ssODN alone (Figure 2).
Transfection eﬃciencies of ssODNs
Myoblasts stably expressing pGFPmut were transfected
with control or targeting oligonucleotides and ssODN
uptake, assessed by immunoﬂuorescence microscopy by
the presence of the CY3 tag, was followed for up to 1
week after transfection (Figure 3). The ﬂuorescent tag
was detected in nearly 100% of cells in cultures treated
with ssODNs 24h after transfection (Figure 3A). FACS
analysis demonstrated similar pattern of distribution of
ﬂuorescence in cells treated with control or targeting
oligonucleotides suggesting equal transfection eﬃciencies
among methylated and unmethylated ssODNs (Figure
3B). Fluorescence remained stable for up to 48h after
transfection and then steadily declined (Figure 3C).
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Amino Acid
Cys (WILD-TYPE)
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Trp
- (STOP)
A
CORGFP: 5’- GGTCGGGGTAGCGGCTGAATCACTGCACGCCGTAGGTCAcgcg-3’
CORGFP: 5’- GGTCGGGGTAGCGGCTGAAGCACTGCACGCCGTAGGTCAcgcg-3’
m5CpGGFP: 5’- GGTCGGGGTAGCGGCTGAATCGCTGCACGCCGTAGGTCAcgcg-3'
CH3
m5CpCGFP: 5’- GGTCGGGGTAGCGGCTGAACCACTGCACGCCGTAGGTCAcgcg-3’
CH3
B
C ssODN
m5CpCGFP
CTLGFP
CORGFP
m5CpGGFP
5’---TGA---3’
3’---ACG---5’
5’---TGA---3’
3’---ACC---5’
CH3
5’---TGA---3’
3’---ACT---5’
5’---TGA---3’
3’---GCT---5’
CH3
Figure 1. Wild-type and mutant GFP sequences and ssODN design. (A) The pGFPmut vector contains a single point mutation at base pair +213 of
the GFP coding sequence that creates a stop codon in this position. ssODNs were designed to target bases in the stop codon to restore GFP
expression. (B) Sequences of targeting (COR
GFP,m
5CpG
GFP,m
5CpC
GFP) and control (CTL
GFP) ssODNs. (C) Annealing of the targeting ssODNs to
the genomic sequence creates a mismatch (box), whereas the control ssODN pair perfectly. The COR
GFP ssODN is designed to induce an A-to-C
conversion that eliminates the stop codon and restores wild-type GFP expression. The m
5CpG
GFP ssODN creates a G:T mismatch in the context of a
m
5CpG, thus mimicking the delamination of m
5C. This will induce a T-to-C substitution which will convert the stop codon into an arginine. The
m
5CpC
GFP ssODN targets the same base as COR
GFP but contains an m
5C modiﬁcation which will lead to an A-to-G conversion and result in a
single amino acid substitution (a tryptophan in place of a cysteine). The CTL
GFP ssODN perfectly complements the mutant sequence and therefore
should not induce any genomic alterations.
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+
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–
Figure 2. Binding of GFP ssODNs to MBD4. A 45-nt oligonucleotide radiolabeled probe corresponding to the region of the pGFPmut vector
targeted for repair was incubated with or without ssODNs and with and without recombinant MBD4 at 37 C for 30min and analyzed by EMSA.
The position of the ssODN/probe complexes is indicated by the thin arrow. The thick arrow above shows the position of the supershift achieved by
the binding of MBD4 with the ssODN/probe complex. MBD4 was unable to form a complex with the target sequence in the absence of an ssODN
bearing a mismatch. No binding of MBD4 to m
5CpG [as assessed using a radioactively labeled m
5CpG (m
5CpG*)] was detected in the absence of the
oligonucleotide sequence targeted for repair.
Nucleic Acids Research, 2009,Vol.37, No. 22 7473By 1 week, ﬂuorescence had almost disappeared providing
clues as to the stability of the oligonucleotides in the cells.
Eﬀects of ssODNs on cell viability
We used a cell viability assay to assess the toxicity of
ssODNs on myoblast cultures for up to 4 days after
transfection (Figure 4). A signiﬁcant increase in non-
viable cells was detected in all cultures treated with
ssODNs 24h after transfection. Oligonucleotides contain-
ing a 5-methyl cytosine appeared to be slightly more toxic
than COR
GFP, but those diﬀerences were not statistically
signiﬁcant. Those diﬀerences, however, were only transient
and disappeared by 48h after transfection. By 72h, the
number of apoptotic cells had returned to levels similar
to those observed in sham transfected cells and remained
stable through the duration of the experiment (Figure 4).
The rate of population growth was determined in cells
treated with the control and targeting ssODNs and
compared with those of cells transfected with vehicle
only (Figure 5). Cell number doubled approximately
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Figure 3. Uptake of ﬂuorescently labeled ssODNs. (A) Immunoﬂuorescence analysis of myoblasts treated with control or targeting ssODNs 2h after
removal of the transfection reagent. Bright ﬂuorescence could be detected virtually all cells transfected with ssODNs. (B) FACS dot-plots of CY3-
positive cells 1day after ssODN transfection. (C) No signiﬁcant diﬀerences were detected in the number of CY3-positive cells transfected with
diﬀerent ssODNs and analyzed for up to 7 days after transfection.
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Figure 4. Cell viability of myoblasts after ssODN transfection. Cell
death was measured by propidium iodine staining for up to 4 days
after transfection of ssODNs and compared with that measured in
control transfected (‘-ssODN’) cells. Signiﬁcant diﬀerences were
observed in all cultures treated with ssODNs 1day after transfection.
*P 0.05. At this time, methylated ssODNs showed a higher percent-
age of propidium iodide-positive cells then cells transfected with
CTL
GFP and COR
GFP. No signiﬁcant diﬀerences were observed at
later time points.
7474 Nucleic Acids Research, 2009,Vol.37, No. 22every 18–20h independently of the type of ssODN used.
No signiﬁcant diﬀerences in population growth were
detected in cultures treated with targeting compared
with control ssODNs.
We next analyzed the eﬀects of ssODNs on cell cycle
progression to determine whether ssODNs could aﬀect
the cell cycle. We did not observe any signiﬁcant
changes in the number of cells present at each phase of
the cell cycle, even when the uptake of ssODNs was at
maximal level within the ﬁrst 48h after transfection
(Table 1). Furthermore, there were no changes related to
the presence of methylated ssODNs compared with
unmethylated ssODNs.
Restoration of GFP expression after targeting
ssODN treatment
Flow cytometry was used to follow restoration of GFP
expression over time in cultures transfected with
ssODNs (Figure 6). No GFP-positive cells were detected
at any time in untransfected cultures or in cultures
transfected with the control ssODN. GFP-positive cells
were detected as early as 1day after transfection of target-
ing ssODNs. Two days after transfection, cultures
transfected with m
5CpG
GFP showed up to 6-fold more
GFP-positive cells than did cultures transfected with
either m
5CpC
GFP or COR
GFP (Figure 6A). GFP-positive
cells were clearly detected in cultures treated with
targeting oligonucleotides by both FACS and microscopic
analyses (Figure 6B and C)
To conﬁrm the stability of the repair process over time,
myoblasts treated with ssODNs were analyzed by western
blot 1 week after ssODN transfection. Expression of GFP
protein was detected in cultures treated with targeting
ssODNs but not with the control ssODNs (Figure 7).
Myoblasts transfected with the m
5CpG
GFP ssODN
showed 2.5-fold higher levels of GFP protein expression
than cells treated with the other targeting ssODNs.
Assessment of gene correction eﬃciency
To further conﬁrm alteration of the GFP sequence
targeted by the ssODNs and to have a precise estimate
of frequencies of gene correction, we analyzed the
genomic sequences by real-time PCR using DNA
samples isolated 3 days after ssODN transfection. The
GFP cDNA mutation in the pGFPmut vector creates a
new restriction site (HinfI; Figure 8A). Using cells
transfected with either COR
GFP or m
5CpC
GFP, digestion
of total genomic DNA with HinfI allowed us to cleave all
copies of the mutant GFP sequence, leaving intact for
ampliﬁcation only that portion of DNA that had under-
gone single base pair alteration rendering it refractory
to HinfI restriction digestion. Ampliﬁcation of a speciﬁc
DNA product was observed only in cells treated with the
targeting ssODNs but not in untreated cells or cells
transfected with the control ssODN (Figure 8B). For
analysis of cells treated with m
5CpG
GFP, we used a similar
strategy but a diﬀerent restriction enzyme because of the
diﬀerent base targeted for correction (Figure 8A). In that
case, digestion of total genomic DNA with BtsI should
eliminate all copies not altered by ssODN-mediated gene
modiﬁcation. Again, ampliﬁcation of a speciﬁc DNA
product was observed only in cells treated with the target-
ing ssODN, but not in untreated cells or cells transfected
with the control ssODN (Figure 8B). The amount of DNA
ampliﬁed was higher in cells treated with m
5CpG
GFP, con-
sistent with the data obtain at the protein level. Direct
sequencing of the products obtained after restriction
enzyme digestion and PCR ampliﬁcation demonstrated
the speciﬁcity of the PCR reaction and conﬁrmed the
presence of the predicted single base pair substitutions at
the genomic level (Figure 8C).
The diﬀerences in fold changes of PCR products
ampliﬁed after HinfIo rBtsI digestion were determined
using a standard delta-Ct method (48). The levels of
gene correction in cells treated with m
5CpG
GFP were
>10-fold higher than those detected using the COR
GFP
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Figure 5. Proliferation rate of myoblasts after transfection. Myoblasts
were seeded at equal density and cultured in growth media for 4 days
after transfection with control and targeting ssODNs. Cells number was
measured daily and growth rate of cells transfected with ssODNs was
compared with that of control transfected (‘-ssODN’) cells at each time
point analyzed. Cells transfected with ssODNs grew at slower rate
compared with control transfected cells. No signiﬁcant diﬀerences
were detected in cultures transfected with nonmethylated and
methylated ssODNs. *P 0.001.
Table 1. Cell cycle analysis of cells after transfection with ssODNs
 ssODN CTL
GFP COR
GFP m
5CpC
GFP m
5CpG
GFP
G1 S G2 G1 S G2 G1 S G2 G1 S G2 G1 S G2
Day 1 44±7 25±1 30±6 44±7 25±1 30±7 41±5 24±1 34±4 38±4 24±2 37±5 44±7 25±1 31±8
Day 2 40±3 26±1 34±3 41±7 26±1 33±7 41±5 30±4 28±7 40±5 27±3 33±7 40±6 27±3 33±7
Day 3 41±6 28±3 31±9 42±4 27±3 29±5 45±1 24±3 31±4 40±6 29±3 31±4 45±2 25±4 30±4
Day 4 46±5 26±1 28±5 43±6 25±3 31±7 42±1 27±1 31±1 36±2 26±2 38±1 45±8 28±3 27±8
Nucleic Acids Research, 2009,Vol.37, No. 22 7475ssODN (Figure 8D) and corresponded to an average of
7% of the total number of copies of the pGFPmut vector
present in culture. No signiﬁcant changes in gene correc-
tion levels were detected when comparing the gene repair
frequencies of m
5CpC
GFP with those achieved using the
COR
GFP ssODN (Figure 8D).
Endonuclease digestion analysis was also used to test
for GFP mRNA expression as the result of the single
base substitution at the genomic level. Total mRNA was
isolated from cells 1 week after transfection and reverse
transcribed prior to HinfIo rBtsI digestion (see ‘Materials
and Methods’ section). The control ssODN failed to
produce any ampliﬁcation of cDNA after restriction
enzyme digestion (Figure 8E). The amount of GFP
mRNA that was refractory to endonuclease digestion as
a result of ssODN-mediated gene editing was consistently
higher in cells treated with the MBD4-binding ssODN as
compared with the other targeting ssODNs. Direct
sequencing of the PCR products was used to conﬁrm
expression of GFP transcripts containing the desired
single base alteration and to ensure speciﬁcity of the
ampliﬁcation product obtained after endonuclease diges-
tion (data not shown).
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Figure 6. Time course and stability of gene repair. (A) FACS analysis was used to follow GFP protein expression over time. GFP was detected as
early as 1day after ssODN transfection and did not increase signiﬁcantly after 2 days. Cells transfected with m
5CpG
GFP showed a signiﬁcantly
greater number of GFP-positive cells as compared with cultures treated with targeting ssODNs, but lacking the methyl-CpG modiﬁcation.
*P 0.008. (B) FACS dot-plots of myoblasts treated with ssODNs 2 and 7 days after transfection of oligonucleotides. (C) Analysis of cultures
by ﬂuorescence microscopy after treatment with the m
5CpG
GFP ssODN and maintained in culture for 4 days. Bright ﬂuorescence intensity was
detected in a subset of replicating cells.
GFP
GAPDH
ssODN: - CTL COR m5CpC m5CpG
Figure 7. GFP protein expression in muscle precursor cells in culture.
Western blot analysis of C57 myoblasts stably expressing the GFP-
mutant vector 1 week after ssODN transfection. Full-length GFP
protein expression was higher in cells treated with m
5CpG
GFP
compared with the other targeting ssODNs. No protein was detected
in cells after transfection with the control ssODN.
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Figure 8. Evidence of ssODN-mediated single base modiﬁcation at the molecular level. (A) The single base mutation on the GFP reporter vector
(base underlined) generates a new restriction site for HinfI endonuclease. Promotion of an A-to-C transversion mediated by the COR
GFP ssODN and
an A-to-G transition mediated by the m
5CpC
GFP ssODN eliminate the restriction site and render the sequence refractory to HinfI digestion and
cleavage. The T-to-C conversion mediated by m
5CpG
GFP eliminates the BtsI restriction site. (B) Genomic DNA was isolated from myoblasts stably
expressing the mutant GFP 1 week after ssODN transfection and treated with either HinfI (for COR
GFP,m
5CpC
GFP and CTL
GFP)o rBtsI (for
m
5CpG
GFP and CTL
GFP). Ampliﬁcation was carried using a forward and a reverse primer encompassing the GFP mutation. No ampliﬁcation was
detected in samples treated with CTL
GFP using either HinfIo rBtsI. A speciﬁc PCR product of identical molecular weight to that obtained after
ampliﬁcation of a wild-type GFP plasmid was detected only in cells treated with targeting ssODNs. (C) Direct sequencing of PCR products obtained
as in (B) by amplifying total genomic DNA having undergone HinfIo rBtsI digestion demonstrated single base alterations at the genomic level and
the speciﬁcity of the ampliﬁcation products. (D) Real-time PCR was used to determine the relative amount of genomic DNA having undergone
ssODN-mediated single base alteration. Cultures treated with m
5CpG
GFP showed 10-fold higher levels of gene editing compared with cultures treated
with m
5CpC
GFP. No signiﬁcant diﬀerences in eﬃciency were detected between cultures treated with the COR
GFP and the m
5CpC
GFP ssODNs. The
total amount of plasmid was determined by ampliﬁcation of the undigested samples using the same primer combinations and was used as internal
standard control to normalize DNA levels. *P=0.001. (E) Total mRNA was isolated 1 week after ssODN transfection and reverse transcribed using
an oligo dT primer. The cDNA was then digested overnight with HinfIo rBtsI depending of the ssODN transfected (A) and ampliﬁed using the same
primers used for the genomic DNA analysis. Modiﬁcation of the mutant GFP sequence using the m
5CpG
GFP ssODN was more eﬃcient than that
observed in cultures treated with targeting ssODNs lacking the 5-methylcytosine (COR
GFP) or the ssODN containing the m
5C modiﬁcation but not
in a CpG context (m
5CpC
GFP).
Nucleic Acids Research, 2009,Vol.37, No. 22 7477Eﬀects of knockdown of MBD4 expression on
ssODN-mediated base alteration
The involvement of MBD4 in the gene correction process
mediated by methyl-CpG-modiﬁed ssODNs was
investigated in cells by downregulating MBD4 expression.
siRNA was used to knockdown expression of MBD4,
leading to a signiﬁcant reduction of MBD4 transcript
levels as soon as 24h after transfection and sustained for
at least 48h after transfection (Figure 9A). The level of
MBD4 protein, as determined by western blot analysis,
was reduced to <10% of control levels (i.e. levels
observed in untransfected myoblasts or myoblasts
transfected with a control siRNA) by 24h after MBD4
siRNA transfection, and this knockdown at the protein
level was maintained for at least another 24h (Figure 9B).
We co-transfected the m
5CpG ssODN with the control
or MBD4 siRNA (or no siRNA) and followed restoration
of GFP protein expression over time by ﬂow cytometry.
The number of GFP-positive cells detected was
signiﬁcantly reduced in cells treated with the MBD4
siRNA compared with those treated with control siRNA
(Figure 10A). No changes in the percentage of GFP-
positive cells were detected in cells co-transfected with
COR
GFP or m
5CpC
GFP and the MBD4 siRNA (data not
shown). The eﬃciency of gene repair under each condition
was conﬁrmed at the DNA level using real-time PCR and
after restriction enzyme digestion of total DNA using
BtsI. The reduction in gene repair activity in cells in
which MBD4 was knocked down was analyzed as a
function of time after MBD4 siRNA transfection. A
decrease in gene correction eﬃciency occurred as early
as 24h after co-transfection of m
5CpG
GFP and the
MBD4 siRNA compared with that achieved after
co-transfection of a control siRNA, and this eﬀect was
even greater at 48h when the siRNA-mediated knock-
down was most eﬀective (Figure 10B).
DISCUSSION
We have studied the ability of a modiﬁed-ssODN
(m
5CpG
GFP), capable of binding MBD4 to direct a site-
speciﬁc modiﬁcation at the genomic level and to mediate
enhanced gene repair compared with an older generation
of correcting ssODN (COR
GFP) unable to recruit the
speciﬁc repair mechanism. Binding was demonstrated
in vitro using recombinant MBD4 and was speciﬁc only
to the ssODN containing the methyl-CpG modiﬁcation
(Figure 2). Gene correction was consistently more eﬀective
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Figure 10. The inﬂuence of MBD4 knockdown on the eﬃciency of gene
editing by a methyl-CpG-modiﬁed ssODN. (A) Expression of GFP
protein was followed over time by FACS analysis. Myoblast cultures
stably expressing the mutant GFP were co-transfected with m
5CpG
GFP
ssODN and either a control siRNA or an siRNA capable of
downregulating MBD4 expression (or with no siRNA). The percentage
of GFP-positive cells was signiﬁcantly decreased 24 and 48h after
transfection in cultures treated with the targeting siRNA compared
with the control siRNA or no siRNA. *P 0.002. (B) Real-time PCR
was used to determine gene editing eﬃciencies of cells transfected with
the m
5CpG ssODN and with either a control siRNA or the MBD4
siRNA. Genomic DNA was isolated 24 and 48h after transfection
and digested with BtsI. The levels of the ampliﬁcation products
in cultures treated with the control siRNA were set at 100%.
Ampliﬁcation products were signiﬁcantly reduced in cells treated with
the MBD4 siRNA at 24h and further reduced at 48h. *P 0.02;
**P 0.004.
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Figure 9. Reduction of MBD4 expression by siRNA interference.
(A) RNA interference was used to downregulate expression of MBD4
in myoblast cultures. Cells were transfected with a targeting or control
siRNA and gene expression was followed over time by quantitative
RT–PCR. Eﬃcient downregulation of MBD4 expression was achieved
by 24h after siRNA transfection and the eﬀect was maintained up
to 48h after transfection. *P 0.001. (B) Western blot analysis was
carried out using total protein isolated 2 days after siRNA transfection.
MBD4 protein was markedly reduced in myoblast cultures treated with
MBD4 siRNA compared with untreated cells or cells treated with the
control siRNA.
7478 Nucleic Acids Research, 2009,Vol.37, No. 22when the MBD4-binding ssODN was used as compared
with an ssODN containing the 5-methylcytosine, but
not in a CpG context or to an ssODN with no
5-methylcytosine modiﬁcations (Figure 8). These data
were conﬁrmed at the protein, transcript and genomic
levels after treatment of cells with targeting ssODNs.
The diﬀerences in gene correction detected do not
appear to be due to preferential uptake of ssODNs con-
taining the m
5CpG sequence nor to an increase in their
stability after transfection, as suggested by FACS analysis
of myoblasts transfected with ﬂuorescently labeled control
and targeting ssODNs and followed for up to 1 week after
transfection (Figure 3). Although some toxicity was
observed in ssODNs containing m
5C, the increase in cell
death was only transient and was not speciﬁc to MBD4-
binding ssODNs as no signiﬁcant diﬀerences were detected
between cells transfected with m
5CpG
GFP and m
5CpC
GFP
oligonucleotides. Finally, no diﬀerences in cell cycle regu-
lation (Table 1) or number of cell divisions (Figure 5) were
observed in cells treated with m
5CpG
GFP as compared
with the other ssODNs or to sham transfected cells.
Together, these data suggest that the diﬀerences in gene
correction detected in myoblast cultures were not due to
the diﬀerences in the ability of MBD4-binding ssODNs to
inﬂuence cell replication, but were likely due to their
ability to increase gene repair. The percentages of GFP-
positive cells detected over time after ssODN transfection
remained stable in all cultures treated with targeting
oligonucleotides, but were signiﬁcantly higher in cells
treated with m
5CpG
GFP ssODN. These results clearly
demonstrate that gene editing in myoblasts is stable over
time, conﬁrming the results previously obtained in our
laboratory using gene editing strategies for the dystrophin
gene (5,10,21). Furthermore, these data demonstrate that
the use of methyl-CpG-modiﬁed ssODNs activating the
BER through MBD4 binding can signiﬁcantly enhance
gene repair.
Restriction enzyme digestion analysis in combination
with real-time PCR demonstrated that the use of
ssODNs containing m
5CpG and capable of binding
MBD4 were able to induce up to 10-fold higher levels of
gene correction than older generation oligonucleotides
lacking any speciﬁc modiﬁcation. In assessing the
frequencies of gene correction, we have taken into consid-
eration several parameters that are likely to yield diﬀerent
estimates of eﬃciency at the genomic, transcript and
protein levels. Such variable include the number of
copies of the pGFPmut plasmid integrated at the
genomic level, level of expression of the plasmid after
G418 selection, the possibility of silencing of plasmid
gene expression in vitro and the sensitivities of the FACS
and western blot analyses to detect low levels of protein
expression. The use of quantitative PCR analysis allowed
us to detect correction events occurring at the genomic
level independently of possible silencing eﬀects and to
estimate frequencies of gene repair per total number of
vectors integrated in the genome. The possibility that the
results obtained were due to PCR artifacts can be excluded
on several grounds. First, each real-time PCR performed
had several internal controls, including DNA isolated
from untransfected cells and cells transfected with the
control ssODN and then subjected to PCR analysis after
restriction enzyme digestion. The absence of ampliﬁcation
in those latter samples ensured us that the endonuclease
digestion had reached completion. Second, PCR analyses
following restriction enzyme digestion were repeated in
triplicate experiments using diﬀerent DNA samples
isolated after transfection. Third, each run was loaded
on agarose gels to conﬁrm that no ampliﬁcation
product, other then the one expected in samples treated
with the targeting ssODNs, would be present in the
reaction. Finally, PCR products obtained after quantita-
tive analysis were excised from the gel and sequenced to
conﬁrm the presence of the desired single base pair
alteration.
MBD4 appears to be a major component of the mech-
anism of gene correction mediated by methyl-CpG-
modiﬁed ssODNs. Downregulation of MBD4 alone was
suﬃcient to prevent the restoration of GFP expression
after modiﬁed ssODN treatment, as demonstrated by
analysis at both the protein and the genomic DNA
levels (Figure 10). These observations are supported by
studies in MBD4 knockout models. Mice lacking MBD4
expression accumulate C-to-T mutations at CpG sites at a
rate of 2- to 3-fold higher than wild-type mice (49,50).
Other repair mechanisms, although important for main-
taining genomic integrity in mammalian cells, do not
appear to play an active role in recognizing deamination
of 5-methylcytosine at m
5CpG sites, nor can they eﬃ-
ciently compensate for the loss of MBD4 in mice.
Therefore, the use of ssODNs containing methyl-CpG
modiﬁcations and capable of annealing to the genomic
sequence creating a mismatched T opposite the G in the
methyl-CpG can be used to speciﬁcally recruit and
activate the MBD4 pathway. The increase in the level of
gene correction by ssODNs containing methyl-CpG
modiﬁcations is likely the result of the eﬃcacy of the
repair mechanisms activated to precisely recognize and
cleave the mismatched base on the genomic DNA
targeted for repair and opposite to the ssODN.
These interpretations were also supported by EMSA
assays which demonstrated that the binding of MBD4
occurred only when a G:T mismatch was created by the
binding of an ssODN containing the m
5CpG modiﬁcation
to the target sequence (Figure 2). The presence of a single
methyl-CpG modiﬁcation on the ssODN was suﬃcient to
recruit MBD4 to the target sequence. Furthermore, the
ability of MBD4 to recognize and bind the targeted
sequence only in the presence of the methyl-CpG-
modiﬁed ssODN annealed to the DNA and creating a
G:T mismatch is a clear evidence that initiation of the
process requires the ssODN to ﬁrst anneal to the target
sequence within the genomic DNA. No MBD4/DNA
complexes were detected when full-length MBD4 protein
was added to the reaction mixture containing the methyl-
CpG-modiﬁed ssODN alone or when MBD4 was added to
the reaction containing ssODNs without a methyl-CpG
even in the presence of the target sequence (Figure 2).
For therapeutic applications, the levels of gene correc-
tion are likely to require higher eﬃciencies than those
currently being achieved in diﬀerent systems using
ssODNs. The use of methyl-CpG-modiﬁed ssODNs is a
Nucleic Acids Research, 2009,Vol.37, No. 22 7479technical advance that enhances gene repair eﬃciency as it
directs the correction event speciﬁcally to the genomic
sequence targeted for repair, diminishing the likelihood
that the repair mechanism might instead alter the
ssODN sequence. Understanding additional steps in the
biochemical mechanisms that mediate the repair will also
lead to further increases in gene repair eﬃciencies.
MBD4-binding ssODNs, although more eﬀective than
unmodiﬁed ssODNs, are sequence speciﬁc and can only
direct conversion of a thymine into a cytosine.
Furthermore, because MBD4 recognizes G:T mismatches
only in the context of CpG sites, the sequence targeted by
the ssODN requires the presence of a guanine immediately
30 of the base targeted for repair. This further limits the
number of mutations that can be targeted for repair in the
context of human diseases. However, it should be noted
that ssODN-mediated gene editing can be targeted to both
the coding and noncoding strands (3,5,12,51,52), thus
increasing the possible target sequences. In addition,
methyl-CpG ssODNs may be useful in oligonucleotide-
mediated exon skipping (21). This approach takes
advantage of the ability of ssODNs to target and disrupt
consensus sequences necessary for intron/exon splicing
and assembly of mature mRNA. The alteration at the
genomic level causes the skipping of one or more exons
during the assembly of mRNA transcripts, and ssODNs
designed to disrupt speciﬁc splicing regulatory elements
can have therapeutic applications in cases where shorter,
in-frame transcripts allow the production of partially
functional proteins (21). This approach has already
being employed in a mouse model of DMD using older
generations of oligonucleotides with encouraging results
(21). Although intron/exon are not speciﬁcally enriched
in TG dinucleotides, that are the speciﬁc targets of
methyl-CpG-modiﬁed ssODNs, such dinucleotides are
frequently present in consensus sequences and other
splicing control elements and are thus potential targets
for altering splicing to restore functional protein expres-
sion from mutant genes. The ability of methyl-CpG-
modiﬁed ssODNs to induce single base pair substitutions
at the intron/exon boundaries of the dystrophin gene is
currently being tested in our laboratory. The development
of a successful approach using methyl-CpG-modiﬁed
ssODNs in oligonucleotide-mediated exon skipping of
the dystrophin gene would have a wide range of clinical
applications. Its use could be applied to the majority of
DMD patients (60–70%) in which large deletions or
frameshift mutations could be corrected by restoring the
dystrophin reading frame.
Random integration, mispairing and activation of
homologous recombination at sites diﬀerent from those
targeted for repair might ultimately preclude this technol-
ogy from entering a clinical scenario. For approaches
aimed at repairing postmitotic muscles cells, those issues
remain less of a concern since the eﬀects are likely to be
conﬁned within a limited number of cells that have under-
gone repair. For those approaches aimed at targeting and
correct muscle stem cells, a detailed analysis of cells under-
gone repair will be critical to demonstrate its safety and
long-term eﬀects. Those studies will have to focus on indi-
vidual cells not just a pool of corrected cells so that the
eﬀects of the correction process can be determined in
detail on a single cell base.
Future studies in our laboratory will be aimed at
determining the safety of gene correction process in
muscle cells and will be focused primarily on assessing
the fate of cells that have undergone repair. The
optimization of culturing conditions capable of maintain-
ing in culture clones isolated after cell sorting will be
critical to characterize those cells and study changes
in gene expression proﬁle in each individual cell that
have undergone gene repair. To date, those studies have
been problematic due to the inability to expand primary
myoblasts isolated using sorting techniques. New
technologies are now being developed that will allow us
to study expression proﬁles from single cells and might
enable us not only to study the eﬀects of gene repair
within each individual cell, but also to determine the
eﬀects of ssODNs immediately after transfection. Those
technologies might ultimately hold the key in determining
the applicability of ssODN-mediated gene correction for
the treatment of many genetic defects.
Ultimately, safe and eﬀective treatments of genetic
diseases using ssODNs will necessitate synergistic eﬀorts
aimed not only at increasing the level of gene repair but
also methods to insure eﬃcient delivery of ssODNs to
all the cells whose correction would be necessary for
maximum therapeutic eﬀect. For diseases in which the
tissue being targeted undergoes continuous turnover
either under normal physiological conditions or in the
setting of the disease, gene correction of the stem or pro-
genitor cells that are responsible for forming new tissue
would be essential to insure sustained therapeutic eﬀects.
These delivery issues are faced by every form of gene
therapy. However, especially for nonviral forms of gene
therapy, the eﬃcacy of the vector once delivered to the
cell, both in terms of magnitude and duration, will be a
critical determinant of the success of that therapeutic
approach. The use of methyl-CpG-modiﬁed ssODNs is
just such a method to enhance the eﬃcacy of ssODN-
mediated gene editing, and may have applications across
a wide range of genetic disorders.
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